FIELD: biochemistry.
SUBSTANCE: invention relates to an antibody specifically binding to a ligand-independent activated form of cMet, a nucleic acid coding same, a kit comprising same, the use of said antibody for the identification of cMet, for diagnosing in vitro an oncogenic disorder, as well as to a method for generating said antibody. Mouse hybridomas for secretion of said antibody are also disclosed. Invention also relates to a method for identifying cMet in a sample, a method for detecting by immunolabeling the presence of a tumour, a method for determining by immunolabeling the expression level of cMet in a tumour, a method for diagnosing by immunolabeling a tumour, as well as a method for determining whether the oncogenic disorder is susceptible to treatment with an anti-cMet antibody using the above antibody.
EFFECT: invention enables to effectively diagnose the presence of an activated cMet-independent ligand in a sample.
17 cl, 9 dwg, 5 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-cMet ANTIBODY AND USE THEREOF FOR DETECTION AND DIAGNOSIS OF CANCER | 2010 |
|
RU2582265C2 |
| ANTI-CXCR4 ANTIBODIES AND USING THEM FOR TREATING CANCER | 2009 |
|
RU2573897C2 |
| HUMANISED ANTI-CXCR4 ANTIBODIES FOR TREATING CANCER | 2011 |
|
RU2595394C2 |
| NEW ANTIBODY TO c-Met | 2011 |
|
RU2607377C2 |
| NEW ANTIBODY TO CXCR4 AND ITS APPLICATION FOR CANCER DETECTION AND DIAGNOSTICS | 2012 |
|
RU2636345C2 |
| NEW ANTIBODIES INHIBITING C-MET DIMERISATION AND USING THEM | 2008 |
|
RU2552161C2 |
| ANTI-c-Met ANTIBODY | 2009 |
|
RU2560257C2 |
| I-3859 ANTIBODY APPLICATION FOR CANCER DETECTION AND DIAGNOSTICS | 2012 |
|
RU2636032C2 |
| ANTIGEN BINDING PROTEIN AND USE THEREOF AS ADDRESSING PRODUCT FOR TREATMENT OF CANCER | 2012 |
|
RU2659094C2 |
| HUMANIZED ANTIBODIES SPECIFIC TO ALPHA-ENOLASE AND METHODS FOR USE IN ANTITUMOR THERAPY | 2014 |
|
RU2761662C2 |
